Pseudoephedrine Behind-The-Counter Status Sought By Pharmacist Group
This article was originally published in The Tan Sheet
Executive Summary
A non-profit advocacy group is urging FDA to switch pseudoephedrine products from OTC status to behind-the-counter sale, claiming the drug is being marketed as a performance enhancer